AgomAb Therapeutics
Biotech · Ghent, BE
Biotech developing therapies targeting fibrosis and Crohn's disease.
Funding history
| Date | Round | Amount |
|---|
| Oct 2023 | Series C Belgian biotech AgomAb Therapeutics raised a $100M Series C led by Fidelity to combat fibrosis. | $100M |
Investors
CanaanDawn BiopharmaEQT Life SciencesFidelity Management & Research Company
Similar companies in Biotech
Explore funding flow on EquityFlow →